RecruitingDiffuse Large B-Cell LymphomaHigh-grade B-cell LymphomaTransformed Lymphoma
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Eligible age
18–70 yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.
Sponsor: Jonsson Comprehensive Cancer Center
You may qualify if…
- ✓ Ages 18-70 years
- ✓ One of the following:
- ✓ Patients undergoing autologous stem cell transplantation (ASCT) or any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy product for:
- ✓ High grade B-cell lymphoma (double or triple hit) with rearrangements in bcl-2 and/or bcl-6, and rearrangement in myc
- ✓ Large B-cell lymphoma with a history of secondary CNS involvement
- ✓ Histologic transformation of indolent lymphoma to large B-cell lymphoma, including marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoplasmacytic leukemia, or Waldenstrom macroglobulinemia
- ✓ High risk international prognostic index (IPI) score 4 or 5, at diagnosis or prior to CAR T-cell leukapheresis
- ✓ Patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for large B-cell lymphoma
You may not qualify if…
- ✕ Cord blood as donor source in alloHCT
- ✕ New York Heart Association Class III or IV
- ✕ Left ventricular ejection fraction \< 50%
- ✕ Estimated glomerular filtration rate \< 30 mL/min
- ✕ Concurrent long-term use of posaconazole or other strong CYP3A4 inhibitors and unable to replace with equivalent medication
- ✕ Acute or chronic graft-versus-host disease (GvHD) \>= stage 3 at time of enrollment
- ✕ Received packed red blood cells (pRBC) transfusion within the past 2 weeks
- ✕ Received platelet transfusion within the past 1 week
Where it's recruiting
California
Los Angeles · Sacramento
Oklahoma
Oklahoma City
Source: ClinicalTrials.gov · NCT05256641 · last updated 2026-03-10